Bemnifosbuvir-Ruzasvir

Phase 3

Atea Pharmaceuticals, Inc. (AVIR)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

AVIRPhase 3$435M

Bemnifosbuvir-Ruzasvir Phase 3 Est. Readout

Bemnifosbuvir-Ruzasvir• HEPATITIS C VIRUS CHRONIC INFECTION880

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

2 competitors in HEPATITIS C VIRUS CHRONIC INFECTION

View Full Landscape

Drug Information

Target Indication

HEPATITIS C VIRUS CHRONIC INFECTION

Clinical Trial

NCT07037277

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AVIR

Atea Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Bemnifosbuvir (BEM)Phase 3

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)

Bemnifosbuvir-Ruzasvir (BEM/RZR)Phase 3

HEPATITIS C VIRUS CHRONIC INFECTION

BemnifosbuvirPhase 2

Chronic Hepatitis C Virus

AT-527Phase 2

Hepatitis C

RuzasvirPhase 2

Chronic Hepatitis C Virus

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts